TrialEuropean urology2024

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.

Primo N Lara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.